Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

Also called NCT02539966

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02539966
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Belgium, Brazil, Denmark, France, Germany, Netherlands, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02539966. Non-randomized; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2019-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
Acronym
FANTOM II
Intervention (Device)
Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
Lead sponsor
REVA Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02539966
Content hash
f772de07cb8c7c4a525323bbf02c1403b3b02b04fc4584b785e5051930b2826f